Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Keisha M. Cawley,Nancy Cecile Bustamante-Gomez,Anveshi G. Guha,Ryan S. MacLeod,Jinhu Xiong,Igor Gubrij,Yu Liu,Robin Mulkey,Michela Palmieri,Jeff D. Thostenson,Joseph J. Goellner,Charles A. O’Brien

DOI: https://doi.org/10.1016/j.celrep.2020.108052

IF: 8.8

2020-09-01

Cell Reports

Abstract:Osteoprotegerin (OPG) inhibits the ability of receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) to stimulate the differentiation, activity, and survival of bone-resorbing osteoclasts. Genetic studies in mice show that osteocytes are an important source of RANKL, but the cellular sources of OPG are unclear. We use conditional deletion of <em>Tnfrsf11b</em>, which encodes OPG, from different cell populations to identify functionally relevant sources of OPG in mice. Deletion from B lymphocytes and osteocytes, two cell types commonly thought to supply OPG, has little or no impact on bone mass. By contrast, deletion of <em>Tnfrsf11b</em> from osteoblasts increases bone resorption and reduces bone mass to an extent similar to germline deletion, demonstrating that osteoblasts are an essential source of OPG. These results suggest that, in addition to producing new bone matrix, osteoblasts also play an active role in terminating the resorption phase of the bone remodeling cycle by suppressing RANKL activity.

cell biology